Products
P27; KIP1 antibody
- Product Name
- P27; KIP1 antibody
- Catalogue No.
- FNab06068
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- cyclin-dependent kinase inhibitor 1B(p27, Kip1)
- Alternative Names
- CDKN1B antibody, CDKN4 antibody, KIP1 antibody, MEN1B antibody, MEN4 antibody, P27 antibody, P27; KIP1 antibody, P27KIP1 antibody
- UniProt ID
- P46527
- Observed MW
- 27 kDa
Application
- Tested Applications
- ELISA, WB, IP, IHC, IF
- Recommended dilution
- WB: 1:200-1:2000; IP: 1:200-1:1000; IHC: 1:50-1:500; IF: 1:50-1:500
Validated Images
NIH/3T3 cells were subjected to SDS PAGE followed by western blot with FNab06068(P27; KIP1 Antibody) at dilution of 1:600
IP Result of anti-P27; KIP1 (IP:FNab06068, 4ug; Detection:FNab06068 1:300) with NIH/3T3 cells lysate 1600ug.
Immunohistochemistry of paraffin-embedded human breast cancer tissue slide using FNab06068(P27; KIP1 Antibody) at dilution of 1:200. heat mediated antigen retrieved with Tris-EDTA buffer(pH9).
Immunofluorescent analysis of ( 4% PFA ) fixed HepG2 cells using FNab06068( P27; KIP1 Antibody) at dilution of 1:50 and Alexa Fluor 488-conjugated Goat Anti-Rabbit IgG(H+L)
- Background
- CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
